drugset / Trial / NCT07455045
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
NaSingle-groupOpen-labelTreatment
Summary
An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.
Timeline
- Start
- 2026-03-01
- Primary completion
- 2027-12-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FZ-AD005 | Other / unclassified | — | Intravenous |